The “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer” was published in JITC August 13, 2021. SITC’s breast cancer expert panel developed this guideline to cover the selection of appropriate immunotherapeutic regimens, companion diagnostics, recognition and management of adverse events, and patient quality of life considerations to reflect the evolving therapeutic landscape for immunotherapy for the treatment of breast cancer.
Anti-PD-1 in combination with chemotherapy is FDA approved for the treatment of advanced triple-negative breast cancer (TNBC) as well as in the perioperative setting for early-stage disease. Ongoing questions remain about the optimal chemotherapy backbone for immunotherapy, appropriate biomarker-based selection of patients for treatment, the optimal strategy for immunotherapy treatment in earlier stage disease, and potential use in histological subtypes other than TNBC. The evidence-based and consensus-based recommendations in this clinical practice guideline are intended to give guidance to cancer care providers treating patients with breast cancer.
August 13, 2021